Abstract Body

HIV-infected persons with detectable cryptococcal antigen (CRAG) in blood have increased mortality compared with HIV-infected persons who are CRAG-negative. This study examined neurocognitive function among persons with asymptomatic cryptococcal antigenemia.

Participants from three prospective HIV cohorts underwent neurocognitive testing at time of antiretroviral therapy (ART) initiation. Cohorts included persons with cryptococcal meningitis (n=90), asymptomatic CRAG+ (n=87), and HIV-infected persons without central nervous system infection(s) (n=125). Asymptomatic CRAG+ participants receiving preemptive fluconazole also had neurocognitive testing additionally performed 4 weeks after ART initiation. Z-scores for each neurocognitive test were calculated relative to an HIV-negative Ugandan population with a composite quantitative neurocognitive performance Z-score (QNPZ-8) created from eight tested domains. Neurocognitive function was measured pre-ART for all three cohorts, and additionally 4 weeks after ART initiation among asymptomatic CRAG+ participants.

Cryptococcal meningitis and asymptomatic CRAG+ participants had lower median CD4 counts (17 and 26 cells/mL, respectively) than the HIV-infected control cohort (233 cells/mL) as well as lower Karnofsky performance status (60 and 70 vs. 90, respectively). The composite QNPZ-8 for asymptomatic CRAG+ (-1.80 Z-score) fell between the cryptococcal meningitis cohort (-2.22 Z-score, P=0.02) and HIV-infected controls (-1.36, P=0.003). Overall neurocognitive function improved after four weeks of ART among the asymptomatic CRAG+ cohort (QNPZ-8 increased to -1.0, P<0.001) to be within one standard deviation of population norms and similar to other HIV-infected persons.

Significant deficits in neurocognitive function were identified in asymptomatic CRAG+ persons with advanced HIV/AIDS even without signs or sequelae of meningitis. Neurocognitive function in this group improves over time after initiation of pre-emptive fluconazole treatment and ART.